Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Seijas-Amigo J, Salgado-Barreira Á, Castelo-Dominguez R, Pérez-Álvarez MT, Ponce-Piñón B, Fernández-Silva M, Rodríguez-Barreiro M, Pereira-Pía M, Iglesias-Moreno JM, Gago-García M, Montáns-García R, Fernandez-Perez A and 10 more

Show all authors

Fraga-Gayoso D, Fernandez-Montenegro M, Riveiro-Barciela B, Rilla-Villar N, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Penas D, Cordero A, Rodríguez-Mañero M, González-Juanatey JR

Diabetes & metabolic syndrome1 Sept 2025Cited by 1 (Europe PMC)

PMID41129847DOI10.1016/j.dsx.2025.103312PepBankPUB-41129847

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

AimsPatients with Type 2 diabetes mellitus face elevated cardiovascular risk. We assessed the effect of GLP-1 receptor agonists on 10-year CVR in a primary prevention cohort.MethodsIn this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers. The primary endpoint was the change in 10-year cardiovascular risk, estimated using the AHA ASCVD Risk Estimator Plus tool at baseline and week 44. Secondary endpoints included weight loss, HbA1c, fasting plasma glucose, and lipid profiles. Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.ResultsIn the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001). Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg). HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).ConclusionsGLP-1 receptor agonists reduce 10-year cardiovascular risk in primary prevention and improve metabolic control. Findings support early use in high-risk people with type 2 diabetes.Trial registrationclinicaltrials.gov Identifier: NCT05136287.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with T2D and obesity, dulaglutide was associated with a body weight reduction from baseline.
In plain wordsIn patients with diabetes and obesity, body weight decreased during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 44 weeksAs given in this study (human).
Measurements
Weight change
−5.6 kg
dulaglutide
Source sentences
Summary
Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
Show in the study text Report a problemFND-4112984707
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and obesity, subcutaneous semaglutide was linked to a weight loss of 8.1 kg, the largest among the GLP-1 receptor agonists compared.
In plain wordsIn adults with type 2 diabetes and obesity, injected semaglutide was linked to 8.1 kg weight loss, the most of the drugs compared.
Peptide
Semaglutide
Outcome
DecreaseWeight change with subcutaneous semaglutide
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 44 weeksAs given in this study (human).
Measurements
Weight change
−8.1 kg
subcutaneous semaglutide
Source sentences
Summary
Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
Show in the study text Report a problemFND-4112984702
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and obesity, oral semaglutide was linked to a weight loss of 6.5 kg.
In plain wordsIn adults with type 2 diabetes and obesity, oral semaglutide was linked to 6.5 kg weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight change with oral semaglutide
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 44 weeksAs given in this study (human).
Measurements
Weight change
−6.5 kg
oral semaglutide
Source sentences
Summary
Subcutaneous semaglutide showed the greatest weight loss (-8.1 kg), followed by oral semaglutide (-6.5 kg) and dulaglutide (-5.6 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
Show in the study text Report a problemFND-4112984703

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In primary prevention patients with T2D, estimated cardiovascular risk decreased from baseline during pooled GLP-1 receptor agonist treatment including dulaglutide.
In plain wordsIn patients with diabetes, estimated cardiovascular risk decreased during pooled treatment with drugs including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseEstimated ten-year cardiovascular risk
Study
n = 105
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Absolute cardiovascular risk change
3.28 percentage points
reduction in primary prevention cohort
Relative cardiovascular risk reduction
13.45%
primary prevention cohort
Source sentences
Summary
In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4112984706
05HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In patients with T2D, HbA1c decreased from baseline during pooled GLP-1 receptor agonist treatment including dulaglutide.
In plain wordsIn patients with diabetes, HbA1c decreased during pooled treatment with drugs including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
8.1%
baseline
HbA1c
6.6%
follow-up
Source sentences
Summary
HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4112984708
06HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In patients with T2D, fasting plasma glucose decreased from baseline during pooled GLP-1 receptor agonist treatment including dulaglutide.
In plain wordsIn patients with diabetes, fasting blood glucose decreased during pooled treatment with drugs including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting plasma glucose reduction
45.8 mg/dL
pooled GLP-1 receptor agonists
Source sentences
Summary
HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4112984709
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes and obesity in primary prevention, pooled GLP-1 receptor agonists (including semaglutide) lowered mean 10-year cardiovascular risk by 3.28 percentage points over 44 weeks.
In plain wordsIn adults with type 2 diabetes and obesity, GLP-1 drugs as a group lowered estimated 10-year heart risk by 3.28 percentage points.
Peptide
Semaglutide
Outcome
Decrease10-year cardiovascular risk change
Study
n = 105
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
10-year CVR change
−3.28 percentage points
primary prevention cohort
Relative reduction
13.45%
primary prevention cohort
Source sentences
Summary
In the primary prevention cohort (n = 105), mean 10-year CVR decreased by 3.28 percentage points, a relative reduction of 13.45 % (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4112984701
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes and obesity, pooled GLP-1 receptor agonists (including semaglutide) improved HbA1c from 8.1% to 6.6%.
In plain wordsIn adults with type 2 diabetes and obesity, GLP-1 drugs as a group lowered HbA1c from 8.1% to 6.6%.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c baseline
8.1%
pooled GLP-1 RAs
HbA1c at week 44
6.6%
pooled GLP-1 RAs
Source sentences
Summary
HbA1c improved from 8.1 % to 6.6 %
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4112984704
09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes and obesity, pooled GLP-1 receptor agonists (including semaglutide) decreased fasting plasma glucose by 45.8 mg/dL.
In plain wordsIn adults with type 2 diabetes and obesity, GLP-1 drugs as a group lowered fasting blood glucose by 45.8 mg/dL.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting plasma glucose change
−45.8 mg/dL
pooled GLP-1 RAs
Source sentences
Summary
HbA1c improved from 8.1 % to 6.6 %, and fasting plasma glucose decreased by 45.8 mg/dL (both p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In this 44-week prospective, non-randomized study, 135 patients with type 2 diabetes mellitus and obesity were included across 13 healthcare centers.
Summary · context
Patients received subcutaneous semaglutide, oral semaglutide, dulaglutide, or other GLP-1RAs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4112984705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT05136287

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Jose Seijas Amigon = 1401 Feb 2022 to 1 Jan 2024

Weight Loss · Diabetes Mellitus, Type 2 · Quality of Life · Safety Issues

Trial page ClinicalTrials.govUpdated 28 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Summary

Results from this study9

Studies that did not test the peptide alone6

Registered trials1

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Version history

Subjects

Publication types

MeSH terms

Keywords